Nigeria’s drug regulatory body, National Agency for Food and Drug Administration and Control (NAFDAC), has announced the immediate recall of all batches of MR.7 Super 700000 capsules after tests revealed the presence of undisclosed pharmaceutical substances.
In a public notice released on Monday, the agency disclosed that the recall was initiated by the product’s manufacturer, StuffbyNainax LLC, following findings by the U.S. Food and Drug Administration (FDA). Laboratory analysis confirmed that the capsules contain sildenafil and tadalafil—active ingredients commonly used in prescription drugs for erectile dysfunction.
NAFDAC explained that both substances belong to a class of medicines known as phosphodiesterase type-5 (PDE-5) inhibitors. Because these ingredients were not declared on the product label, the capsules are classified as unapproved drugs with unverified safety and effectiveness.
The product, marketed online as a dietary supplement for male enhancement, violates regulatory standards, as supplements are not permitted to contain prescription drug ingredients.
The agency has therefore directed that all batches of MR.7 Super 700000 capsules currently in circulation be withdrawn immediately. Consumers and distributors in possession of the product have been advised to stop its use or sale and return it to the nearest NAFDAC office.
NAFDAC also called on healthcare professionals and members of the public to report any suspected counterfeit, substandard medicines, or adverse reactions through its official reporting channels.
Highlighting the health risks, the agency warned that undisclosed sildenafil or tadalafil can interact dangerously with nitrate-based medications—such as nitroglycerin—commonly prescribed for heart conditions. This interaction may lead to a sudden and severe drop in blood pressure, which can be life-threatening.
Individuals with underlying conditions such as diabetes, hypertension, high cholesterol, or cardiovascular disease—especially those on nitrate therapy—are considered particularly vulnerable.
The development comes amid heightened regulatory scrutiny of unsafe and falsified medicines in Nigeria. Recently, NAFDAC also issued a warning about counterfeit Avastin (Bevacizumab) injections circulating within the country.
Reaffirming its mandate, the agency emphasized its continued commitment to safeguarding public health through strict monitoring of the safety, quality, and efficacy of regulated products nationwide.
Comments